Liquidia Corporation
LQDA
$0.51
Change (1 day)
$16.99
Year High
$8.26
Year Low
Categories
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
P/B ratio for Liquidia Corporation (LQDA)
P/B ratio as of 2023: 16.53
According to Liquidia Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 16.53. At the end of 2022 the company had a P/B ratio of -1.11.
P/B ratio history for Liquidia Corporation from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 16.53 |
| 2022 | -1.11 |
| 2021 | -0.78 |
| 2020 | -0.36 |
| 2019 | 2.26 |
| 2018 | 8.30 |
| 2017 | -2.83 |
| 2016 | -3.10 |